Shukra Pharmaceuticals share price
NSE: SHUKRAPHARBSE: 524632Pharmaceuticals & BiotechnologySmall Cap
Shukra Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1994 on BSE, Aug 2026 on NSE
Last close ₹75.06up ₹3.14 (4.37%)BSE ₹74.99
Share price at the NSE close on 29 Oct 2026. Previous close ₹71.92.
29 Oct: open ₹72.23, high ₹79.88, low ₹71.33
52-week range of BSE trades to 29 Oct 2026
₹26.30Low, 27 May 2026₹79.90High, 29 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,300 Cr1,258th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 91.54
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 36.73
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.01%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 47.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 47.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,64,44,73013.3% delivered
Results
Standalone, as consolidated accounts are on record for only 1 of the last ten years; ₹ crore.Shukra Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +115.0%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +256.2%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹24 Crup 273.20%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹15 CrQuarter to Mar 2026: −₹1.73 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 63.9%
Revenue by quarter
Peak revenue ₹39 Cr, quarter to Dec 2025; lowest ₹5.39 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Jun 2026, ₹15 CrA loss in 1 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.6 | 10.6 | 13.3 | 5.4 | 5.9 | 39.1 | 6.3 | 23.5 |
| Net profit | 0.5 | 3.2 | 5.4 | 1.0 | 2.4 | 20.4 | −1.7 | 15.0 |
| Net margin | 9.7% | 29.9% | 40.6% | 19.1% | 40.5% | 52.0% | −27.4% | 63.9% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹57 Crup 74.01%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹22 Crup 130.26%
- Net margin
- 38.9%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹12 Cr, differs from its quarters added, ₹10 Cr. From the year to Mar 2022, the company's revenue for that year, ₹20 Cr, differs from its quarters added, ₹18 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.2 | 5.4 | 5.7 | 11.8 | 11.2 | 20.5 | 58.8 | 74.6 | 32.6 | 56.7 |
| Net profit | 0.7 | 1.0 | 0.5 | 0.0 | 0.0 | 0.8 | 4.4 | 18.5 | 9.6 | 22.0 |
| Net margin | 14.0% | 19.1% | 8.1% | 0.3% | 0.3% | 3.7% | 7.5% | 24.9% | 29.4% | 38.9% |
Standalone. Years to March. The latest is shaded.
Business segments
One segment, Pharmaceutical Segment, carries all the revenue in the year to Mar 2026.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the years to Mar 2020 and Mar 2022: days before it are of the company before the change.Shukra Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 82% of 996 trading days over the last 5 years.
LowestHighest
Its median45.37Industry median28.22
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 99% of 909 trading days over the last 5 years.
LowestHighest
Its median7.22Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 99% of 1,871 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +38.9% | +127.3% | −38.9% | 0.0% |
Longer windows are left empty: a corporate action or price step on 2023-02-02 that cannot be sized sits inside this window.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 6,002 | 0.08% | ₹0.04 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 2,830 | 0.08% | ₹0.02 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Shukra Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Shukra Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Aarti DrugsAARTIDRUGS | 4,098 | 21.44 | 2.65 | +10.5% | +1.2% | 13.1% | 12.4% | 0.45% |
 Kwality PharmaceuticalsKPL | 3,819 | 47.12 | 11.52 | +37.9% | +86.7% | 27.2% | 25.0% | 0.00% |
 Ind-Swift LaboratoriesINDSWFTLAB | 3,564 | 62.17 | 2.57 | +113.3% | – | 4.5% | 2.0% | 0.00% |
 Unichem LaboratoriesUNICHEMLAB | 3,555 | 11.66 | 1.31 | +9.4% | – | 11.8% | 3.3% | 0.00% |
 Solara Active Pharma SciencesSOLARA | 3,162 | 85.59 | 2.20 | +27.3% | – | 2.7% | 6.4% | 0.00% |
 HikalHIKAL | 2,520 | – | 2.10 | −5.4% | −153.4% | −2.7% | 3.5% | 0.29% |
 Fredun PharmaceuticalsFREDUN | 2,456 | – | 8.83 | – | – | – | 18.8% | 0.02% |
 Dishman Carbogen AmcisDCAL | 2,343 | 144.97 | 0.35 | +0.2% | −84.5% | 0.3% | 1.4% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Shukra Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.01 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 21 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.01 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Shukra Pharmaceuticals announcements
Oct 2026
22 Oct · Board meeting
Not held on this date
19 Oct
12 Oct
6 Oct · Board meeting
6 Oct
Shukra Pharmaceuticals share price by year
Each calendar year to 2025.Shukra Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 59.25 | – | 62.36 | 12.09 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 21 Mar 2025.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 72.10 | 76.50 | 71.60 | 71.92 | 73.79 | 1,11,21,334 | 14.6% |
| 27 Oct 2026 | 68.50 | 74.24 | 68.07 | 71.54 | 71.46 | 1,14,43,819 | 14.7% |
| 26 Oct 2026 | 64.51 | 69.45 | 59.01 | 67.46 | 65.30 | 1,04,56,520 | 17.8% |
| 23 Oct 2026 | 64.05 | 67.04 | 50.03 | 64.46 | 57.46 | 1,99,54,068 | 17.8% |
| 22 Oct 2026 | 67.01 | 67.77 | 62.05 | 62.53 | 62.89 | 43,40,855 | 36.7% |
| 21 Oct 2026 | 68.90 | 68.90 | 68.25 | 68.36 | 68.35 | 27,42,819 | 65.9% |
| 19 Oct 2026 | 68.12 | 69.50 | 68.12 | 68.62 | 68.87 | 13,82,685 | 42.4% |
| 16 Oct 2026 | 66.79 | 71.73 | 66.78 | 68.88 | 69.39 | 78,59,711 | 26.6% |
| 15 Oct 2026 | 67.25 | 67.28 | 66.59 | 66.79 | 66.86 | 8,69,879 | 50.5% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 21 Mar 2025 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
| 19 Apr 2024 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
| 2 Feb 2023 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
| 6 Apr 2015 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it.
Company details
- NSE symbol
- SHUKRAPHAR
- BSE code
- 524632
- ISIN
- INE551C01044
- Industry
- Pharmaceuticals & Biotechnology
- CIN
- L24231GJ1993PLC019079
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1993
- Registered office
- 3rd floor, Dev House, Opp. WIAA, Judges Bungalows Road, Bodakdev, Ahmedabad 380054, Gujarat
- Share registrar
- Purva Sharegistry (India) Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments